BIOSYNEX (ALBIO.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALBIO - FR0011005933 - Common Stock
ALBIO.PA Key Statistics, Chart & Performance
The current stock price of ALBIO.PA is 0.59 EUR. In the past month the price increased by 18%. In the past year, price decreased by -54.69%.
ALBIO.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1MDT.MI | MEDTRONIC PLC | 17.59 | 107.77B | ||
| 2M6.DE | MEDTRONIC PLC | 17.36 | 106.36B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.62 | 50.20B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 15.41 | 21.95B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 15.38 | 21.92B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 15.36 | 21.90B | ||
| BIM.PA | BIOMERIEUX | 28.5 | 13.02B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 137.87 | 4.15B | ||
| DIA.MI | DIASORIN SPA | 20.13 | 3.73B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 25.03 | 3.60B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.6 | 1.28B | ||
| ELN.MI | EL.EN. SPA | 21.7 | 1.12B |
Related stock screener links
About ALBIO.PA
Company Profile
Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 486 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Company Info
BIOSYNEX
22 Boulevard Sebastien Brant
Illkirch-Graffenstaden GRAND EST FR
Employees: 515
Phone: 33388787887
BIOSYNEX / ALBIO.PA FAQ
What does ALBIO do?
Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 486 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
What is the current price of ALBIO stock?
The current stock price of ALBIO.PA is 0.59 EUR. The price decreased by -0.67% in the last trading session.
What is the dividend status of BIOSYNEX?
ALBIO.PA does not pay a dividend.
What is the ChartMill rating of BIOSYNEX stock?
ALBIO.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is BIOSYNEX worth?
BIOSYNEX (ALBIO.PA) has a market capitalization of 11.06M EUR. This makes ALBIO.PA a Nano Cap stock.
ALBIO.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALBIO.PA. When comparing the yearly performance of all stocks, ALBIO.PA is a bad performer in the overall market: 94.47% of all stocks are doing better.
ALBIO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA. Both the profitability and financial health of ALBIO.PA have multiple concerns.
ALBIO.PA Financial Highlights
Over the last trailing twelve months ALBIO.PA reported a non-GAAP Earnings per Share(EPS) of -4.28. The EPS decreased by -42.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.65% | ||
| ROE | -161.36% | ||
| Debt/Equity | 0.32 |
ALBIO.PA Forecast & Estimates
For the next year, analysts expect an EPS growth of 475% and a revenue growth 15.05% for ALBIO.PA